U.S. Food and Drug Administration Commissioner Scott Gottlieb in a speech Thursday hinted rebates paid by drug manufacturers to payers and pharmacy benefit managers could be subject to review, The Hill reports.
Gottlieb said the anti-kickback law which safeguards those rebates could be changed to help boost market competition and reduce drug prices.
“One of the dynamics I’ve talked about before that’s driving higher and higher list prices is the system of rebates between payers and manufacturers,” Gottlieb said. “And so what if we took on this system directly, by having the federal government reexamine the current safe harbor for drug rebates?”
To read the full report on The Hill, click here.